Glycoprotein hormone alpha-2

Also known as: Putative secreted protein Zsig51, Thyrostimulin subunit alpha, GPHA2, Q96T91

Glycoprotein hormone alpha-2 (GPHA2), also known as thyrostimulin subunit alpha, forms a heterodimer with glycoprotein hormone beta-5 (GPHB5) to create thyrostimulin, a non-classical glycoprotein hormone. Its primary mechanism of action involves binding to and activating the thyroid-stimulating hormone receptor (TSHR), which is canonically associated with thyroid function. This activation stimulates intracellular cyclic AMP (cAMP) production via G-protein-coupled receptor signaling, mirroring the downstream effects of thyroid-stimulating hormone (TSH) but with distinct tissue distribution and regulatory properties. Current research on GPHA2 remains at an experimental stage, with limited published studies (2 PubMed references). Key findings indicate that thyrostimulin exhibits higher potency than TSH at the TSHR in vitro, suggesting a potential role in fine-tuning thyroid hormone regulation or acting in tissues where TSHR is expressed outside the thyroid, such as the pituitary or gonads. However, the physiological significance of GPHA2 in vivo is not fully characterized, and its expression patterns and functional redundancy with TSH require further investigation. Clinically, GPHA2's relevance is speculative but may involve conditions of thyroid dysfunction, such as resistance to TSH or atypical hyperthyroidism, where thyrostimulin could contribute to aberrant TSHR activation. Its potential as a therapeutic target or biomarker remains unexplored due to the scarcity of data. For research purposes only — not medical advice.

Key data

Mechanism of action

Functions as a heterodimeric glycoprotein hormone with GPHB5 able to bind and activate the thyroid-stimulating hormone receptor (TSHR), leading to increased cAMP production (PubMed:12045258). Plays a central role in controlling thyroid cell metabolism (PubMed:12045258)

Research & studies

Frequently asked questions

Related peptides